NCT00648674撤回4 期
A Prospective, Single-Site Study to Identify and Characterize the Molecular Mechanisms of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers
适应症
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 主要终点
- To use the novel technology of microarrays to identify and characterize the molecular mechanisms through which Apligraf promotes healing of venous leg ulcers.
研究概览
简要总结
Single site clinical study utilizing the novel technology of microarrays to identify and characterize the molecular mechanisms through which Apligraf promotes healing of venous leg ulcers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subject has non-infected partial or full-thickness venous leg ulcer for a duration of four weeks or greater which has not adequately responded to conventional therapy
- •Stage II or III ulcer as defined by the IAET/WOCN ulcer classification guide listed in Appendix IV.
- •Subject is female and 18 years of age or older.
- •Subject with venous leg ulcer (target ulcer) between 5 - 40 cm2 in size.
- •Sexually active females must be practicing a medically proven form of contraception during the course of the study period.
- •Subject or legal guardian must have read, understood and signed an institutional review board (IRB) approved Informed Consent Form.
- •Subject and/or legal guardian must be able and willing to follow study procedures and instructions.
排除标准
- •Subject whose target ulcer has healed 60% or greater in area from post debridement (if applicable) Baseline Screen (Visit 1) to post debridement Day 0 (Visit 2) as determined by wound tracings.
- •Subjects who are being treated with VAC® (Vacuum Assisted Closure™) Therapy.
- •Subject has arterial disease as determined by an Ankle Brachial Index (ABI ) of <0.
- •Subject with any systemic condition like uncontrolled diabetes mellitus (glycosylated HbA1C > 12%), cancer (biopsy confirmed active malignancy), positive HIV test, or any disorder(s) that may compromise wound healing.
- •Subjects who are currently receiving, or have received at any time within one month prior to entry into the study, corticosteroids (>15 mg/day), immunosuppressive agents, radiation therapy, hemodialysis or chemotherapy. Anticipated use of the above agents will exclude subjects from entry into the study.
- •Clinical vasculitis, severe rheumatoid arthritis, and other collagen vascular diseases.
- •Signs and symptoms of cellulitis or osteomyelitis.
- •Necrotic or avascular ulcer beds.
- •Venous leg ulcer with exposed bone, tendon or fascia.
- •Subject with the presence of recent infections in the area intended for treatment.
- •Known hypersensitivity to bovine collagen or to the components of the Apligraf agarose shipping medium.
- •Subject who is lactating or pregnant (hCG positive as determined by lab testing).
- •Subject with liver (ALT/SGPT, ALP, AST/SGOT, bilirubin, Albumin, total protein, LDH) and/or renal function (BUN and creatinine) tests greater than 2 x upper limit of normal (ULN) or Albumin < 2.5 mg/dL.
- •Subject enrolled in any wound or investigational device study for any disease within the past four weeks.
- •Subject previously treated at target site with Apligraf, Dermagraft or any other cell therapy at the target site.
- •Subject with a history of alcohol or substance abuse within the previous year, which could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes.
- •Subject who, in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol
结局指标
主要结局
To use the novel technology of microarrays to identify and characterize the molecular mechanisms through which Apligraf promotes healing of venous leg ulcers.
时间窗: 2 weeks
次要结局
- Determine growth factors induced by Apligraf in the wound(2 weeks)
- Safety endpoints assessed by monitoring adverse events(5 months)
- Determine how venous leg ulcer (VLU) wounds transition from chronic to acute wound healing(2 weeks)
- Examine how Apligraf rescues deficiencies of chronic wounds (VLU) and promotes transition from chronic to acute wound(2 weeks)
- Determine growth factors suppressed by Apligraf in the wound(2 weeks)
研究者
相似试验
已完成
4 期
A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg UlcersVenous UlcerNCT01327937Organogenesis30
已完成
1 期
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.Psoriasis VulgarisNCT03898583LEO Pharma15
招募中
不适用
A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint BlockadePneumonitis, InterstitialImmunotherapyImmune-related Adverse EventsNCT04807127Universitaire Ziekenhuizen KU Leuven60
已完成
1 期
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy VolunteersHealthy AdultsNCT02767089Pfizer37
进行中（未招募）
不适用
The Future Management of Patients With Neoplasms of the Gastro-intestinal TractPancreatic AdenocarcinomaColon CancerCholangiocarcinomaNCT06728358Fondazione Policlinico Universitario Agostino Gemelli IRCCS300